-
| Exchange | NASDAQ |
|---|---|
| CurrencyCode | USD |
| ISIN | US3847471014 |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Market Cap | 2B |
|---|---|
| PE Ratio | None |
| Target Price | 67.7143 |
| Beta | nan |
| Dividend Yield | None |
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for GRAL using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2026